The DEA Is Throwing a Party for Beating Fentanyl. The Chemists Already Moved On.

Last summer, dozens of people in Baltimore were rushed to a hospital in a single stretch of days after being exposed to a designer benzodiazepine nobody had bothered to name yet. Every one of them survived — not because the drug was safe, but because enough of them were near enough to help, fast enough, that this time the supply’s newest improvisation didn’t win. That is the entire story of the American overdose crisis in 2026, compressed into one incident: a real, historic decline in deaths, running on a supply chain that reinvents itself faster than the agencies tracking it can issue a health alert.

You are reading this the same week the Drug Enforcement Administration held a summit to celebrate that decline. You are also reading it the same season the government that convened that summit made it against the rules to spend its own grant money on the strips that tell someone what’s actually in the dose they’re about to take.

The government is holding a parade for beating fentanyl while defunding the only tool that tells you what replaced it.

Both things are true. Neither cancels the other out. That’s the story.

The number is real. So is the victory lap.

Start with what nobody disputes: synthetic opioid deaths fell 22% in a single year, from 48,913 in 2024 to 38,084 in 2025, according to provisional CDC data cited across the reporting on this story. Total drug overdose deaths are down 14% year over year, to roughly 69,973 — a fall from the nearly 113,000 recorded at the August 2023 peak. Lori Ann Post, a researcher at Northwestern who has spent years tracking this data, put it plainly: “This is unprecedented and historic, for the longest consecutive months of decline” on record. She is not exaggerating. Some counties — parts of Maine, for people under 25 — reported zero overdose deaths over an eleven-month stretch. Virginia posted a decline north of 40% in a single year.

The DEA used that momentum to convene the inaugural Fentanyl Free America Summit July 12–16 in Orlando, folded into CADCA’s Mid-Year Training Institute — more than 2,500 people, including 350 youth, and a speaking lineup that ran from Attorney General Todd Blanche to ONDCP Director Sara Carter. The White House’s own accounting of the six weeks leading into the summit: more than four million fentanyl pills and 1,158 kilograms of fentanyl powder seized, a haul the administration says represents upward of 50 million potentially deadly doses pulled off the street. Framed around three pillars — Protect, Prevent, Support — the summit was, on its own terms, a genuine and defensible thing to hold. People are alive this year who would not have been three years ago. That deserves to be said plainly, not buried under a caveat.

Here’s the caveat anyway, because it matters more than the parade: enforcement did not do this alone, and the parts that weren’t enforcement are the parts now losing their funding.

The chemists didn’t get the invitation

While DEA agents were being thanked on stage in Orlando, a coroner in Richland County, South Carolina was explaining to reporters what her office had just started finding in bodies. “That’s where we found the cychlorphine,” Naida Rutherford said — a synthetic opioid analog that, as of a few months ago, most toxicologists in the country had never had reason to screen for. Nabarun Dasgupta, who runs street-drug surveillance work out of the University of North Carolina, is careful not to overstate what’s happening: “Why those in particular are being put into the drug supply is a bit of a medical mystery at this point.” Ed Sisco, a research chemist at the National Institute of Standards and Technology whose lab processes seized and discarded drug samples from across the country, described the pace of novelty in blunter terms: “Once a month or every other month, we’re encountering something that we’ve never seen before.”

Translate that: the illicit chemistry supply chain is not standing still just because the number on the CDC’s dashboard is finally moving in the right direction. It is doing what unregulated markets under enforcement pressure always do — substituting, diluting, re-formulating, staying one analog ahead of the schedule that would make the newest version illegal.

Translate that: the illicit chemistry supply chain is not standing still just because the number on the CDC’s dashboard is finally moving in the right direction.

Two substitutions matter most right now, and neither is fentanyl. The first is nitazenes — synthetic opioids originally developed and shelved decades ago as pain medications, some variants up to ten times as potent as fentanyl by weight. Here’s the calibrated version, not the panic version: as of the most recent surveillance data, nitazenes still make up under 2% of tested street samples nationally. That’s real, it’s rising, and it is nowhere near a dominant threat yet — the coverage has, at points, gotten ahead of the numbers. Naloxone still works on nitazenes; they’re opioids.

The second substitution is the one that should actually worry you, because naloxone does nothing for it. Medetomidine is a veterinary sedative — not an opioid, not touched by the drug you or a friend might be carrying in a purse or a glovebox for exactly this kind of emergency. It’s being called the direct successor to xylazine, the “tranq” adulterant that spent the last several years teaching harm reduction workers to treat wound care as seriously as overdose reversal. Detections in Maryland alone rose 97.6% between 2021 and 2023, and the substance has kept spreading since it first surfaced on the East Coast in 2024. The CDC and the White House drug policy office took the unusual step of issuing a joint health alert on it in March — unusual because CDC health alerts on a single street adulterant are rare, and rarer still jointly with ONDCP.

Here is the plain-language version, because the mechanism is the whole point: naloxone reverses opioid overdoses by knocking opioid molecules off the receptors in your brainstem that slow your breathing to a stop. Medetomidine doesn’t touch those receptors — it works through a completely different pathway, the same one veterinarians use to sedate large animals for surgery. You can give someone every dose of naloxone in the box and their breathing still won’t come back, because there’s nothing there for the naloxone to displace. If you carry naloxone — and you should still carry it, because most of what’s out there is still fentanyl and naloxone still saves those lives — know that it is not a guarantee anymore. It never fully was. It’s less of one now.

The tool that catches this is the one they just defunded

This is the part that should make you angry, and the anger is earned.

Fentanyl test strips and their medetomidine and xylazine equivalents are the closest thing the supply-side chaos has to an early warning system — a way for a person to know, thirty seconds before they use, that what they’re holding isn’t what they think it is. BTNX’s medetomidine strips reliably detect the drug above 1,000 ng/mL, and researchers studying strip accuracy have pushed hard for wider distribution specifically in regions where medetomidine has started showing up in overdoses. That’s the system working as designed: new threat, new test, faster distribution.

On April 24, 2026, SAMHSA sent grantees an updated Dear Colleague letter that pulled federal grant dollars out from under exactly that system. Drug-checking strips — fentanyl, xylazine, medetomidine, all of it — can no longer be purchased with the federal money that funds most harm reduction programs in this country. Overdose hotlines lost their funding eligibility in the same letter. The American Society of Health-System Pharmacists formally opposed the change — not a fringe advocacy group, but the professional body representing the pharmacists who dispense the naloxone this same administration is, correctly, trying to get into more hands.

The Kentucky Harm Reduction Coalition distributed 48,465 fentanyl test strips in the first quarter of this fiscal year alone — a working, high-volume program, doing exactly the surveillance-adjacent work that catches a medetomidine spike before it becomes a cluster of deaths. In April, the organization learned its $400,000 SAMHSA grant was gone. It is now operating on roughly a month of reserves. Nobody in Washington had to shut Kentucky Harm Reduction Coalition down directly. They just made the thing it does ineligible for the money that kept it running.

They just made the thing it does ineligible for the money that kept it running.

Arizona’s own version of this contradiction landed the same week. AHCCCS published its Opioid Antagonist Distribution Initiative — the state’s naloxone distribution solicitation — on July 10, after the release was delayed by, in the state’s own words, “a technical issue affecting the grant management system.” A software bug held up naloxone money in the same month the federal government was making a political choice to hold up test strip money. One was an accident. The other wasn’t. Both mean a slower supply of the tools that keep people alive long enough to get into treatment — which is, per the Rize Treatment & Recovery desk’s ongoing coverage, the whole ballgame.

We have watched a government decide that a cheap thing which keeps people who use drugs alive sends the wrong message before. In 1988, Congress — led by Senator Jesse Helms — banned the use of federal funds for the syringe exchange programs that were, at the time, the single most effective tool available for slowing HIV transmission among people who inject drugs. The ban held, with only brief interruptions, for the better part of three decades, while HIV moved through communities that a needle exchange would have protected. Nobody who voted for that ban intended to spread HIV. They intended to withhold what looked, to them, like an endorsement of drug use. The virus did not care about the intention. It cared about the needles it was allowed to reach.

That is the pattern repeating in a test strip today. Nobody signing the April letter intended to make it harder to know what’s in the supply. They intended to signal that the federal government does not fund the infrastructure of drug use. Medetomidine does not care about the signal. It cares about who finds out it’s in the batch before they use it, and who doesn’t.

What’s still yours, even this week

None of this means the ground has fully shifted under you. Naloxone itself — the actual medication, not the hotline or the test strip — remains federally funded and, in Arizona, is moving through a new distribution round right now, technical glitch notwithstanding. Most of what’s in the supply is still fentanyl, and naloxone still reverses fentanyl. Test strips are not illegal to possess or distribute anywhere they were legal last month — they’re only harder for a grant-funded program to afford, which is a five-alarm problem for the organizations doing this work and a real but different problem for the person deciding whether to test before they use tonight. If you have access to a strip, use it. If your local program just lost its budget, that program did not lose its knowledge, its relationships, or its reason for existing — it lost one funding stream, on one date, that people are already organizing to replace.

The DEA earned its summit. The number is real, and so are the four million pills that didn’t reach anyone. But a supply chain smart enough to invent cychlorphine before toxicologists have a routine screen for it is not a supply chain that enforcement alone is going to out-innovate. The agencies that spent this month taking a victory lap are the same ones that, in the same season, made it harder to know what’s actually killing the people enforcement doesn’t reach in time. You don’t get to claim the decline and defund the thing partly responsible for it in the same news cycle. Pick one.